Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 48Neoplasm Metastasis 11Hereditary Sensory and Autonomic Neuropathies 7Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Ovarian Neoplasms 5Neoplasms 5Triple Negative Breast Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Lymphangioma 3Hyperglycemia 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Head and Neck Squamous Cell Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Breast Cancer 2Vascular Malformations 1Uveal Melanoma 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Stomach Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Alpelisib × Clear all
NCT02144038 2020-12-17

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Novartis

Phase 1 Completed
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡